Pfizer replaced Merck as the pharmaceutical company most respected by physicians, according to Scott-Levin.
Pfizer replaced Merck as the pharmaceutical company most respected by physicians, according to a new strategic study by Scott-Levin, Newtown, PA.
Good research and development, credibility, educational orientation, sensitivity to pricing concerns and orientation to patient information were strengths that physicians judged superior in Pfizer.
"Firms with a strong research and development reputation tend to perform better in overall company rankings," noted Joy Scott, CEO of Scott-Levin. "Pfizer's high position can also be attributed to strong sales and marketing and innovative new products."
Recent drug launches, such as Viagra, Lipitor and Aricept, boosted Pfizer's ranking, according to Scott-Levin.
Pfizer was ranked first by nurse practitioners, physician assistants and HMO medical directors as well. However, pharmacists, pharmacy drug chain executives, drug wholesalers, hospital buying groups and nursing home pharmacy consultants rated Merck as the most respected company. Novartis was voted most respected by pharmacy benefit management executives and HMO pharmacy directors.
Broken down among physician specialty groups, other pharmaceutical companies fared slightly better. Although general practitioners and internists stood by Pfizer, OB/GYNs rated Johnson & Johnson most respected, pediatricians cast their votes for Abbott Laboratories and psychiatrists gave the nod to Eli Lilly.
In 1996, when Scott-Levin last surveyed health care professionals about corporations and respect, Merck was ranked first by physicians. Scott-Levin has surveyed physicians on their preferences biennially since 1992. PR
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.